CTC
PBE icon

Central Trust Company’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Central Trust Company’s Portfolio PBE Stock Details PBE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-10
Closed – – 1176
2019
Q2 		$0 Buy
+10
New +$519 ﹤0.01% 1166

Other funds holding PBE

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
PA
PFG Advisors Phoenix, Arizona $1.98B AUM 28.18% 1-Year Est. Return

Central Trust Company's PBE Position: Q3 2019 in Review

Central Trust Company sold out of Invesco Biotechnology & Genome ETF (PBE) in Q3 2019, closing a stake of 10 shares.

Central Trust Company first reported a position in PBE in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 73 funds tracked by Wall St. Rank hold PBE as of Q3 2019.

  • Central Trust Company reported no remaining Invesco Biotechnology & Genome ETF position as of Q3 2019 after selling out during the quarter.
  • Central Trust Company sold 10 Invesco Biotechnology & Genome ETF shares in Q3 2019.
  • Central Trust Company first reported a position in Invesco Biotechnology & Genome ETF in Q2 2019 and held it in 1 quarter.
  • Central Trust Company's Invesco Biotechnology & Genome ETF position peaked at $0 in Q2 2019.
  • 73 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2019.

Based on Central Trust Company's 13F filing for Q3 2019, filed 28 Oct 2019.